Concentrations of drugs acting in the lungs are difficult to measure, resulting in relatively unknown local pharmacokinetics. The aim of this study is to assess the potential of exhaled breath condensate (EBC) as a matrix for pharmacokinetic analysis of inhaled and intravenous medication. A 4-way crossover study was conducted in 12 volunteers with tobramycin and salbutamol intravenously and via inhalation. EBC and plasma samples were collected postdose and analysed for drug concentrations.
discourages use in vulnerable patients, children and healthy subjects. Therefore, new sampling matrices are needed. A matrix of interest is exhaled breath condensate (EBC). 5 EBC is obtained by cooling exhaled breath through contact with a cold condenser. Samples are collected as fluid or frozen material and represent the ELF, diluted in condensed water from inhaled air and some saliva. [6] [7] [8] EBC application for biomarker quantification has been limited by poor reproducibility and high variability. 9 Several solutions have been proposed to improve reliability of EBC, such as to control for sample dilution factor obtained via EBC urea concentrations. [10] [11] [12] Drug concentrations have already been measured in exhaled breath following administration of several drugs. [13] [14] [15] [16] [17] [18] Nonetheless, no studies have assessed EBC concentrations after inhaled administration or reported proper concentration-time curves of EBC. The aim of this study is to assess the potential of EBC as a matrix for pharmacokinetic analysis of 2 common respiratory drugs: salbutamol and tobramycin.
| MATERIALS AND METHODS
This study was conducted at the Centre of Human Drug Research in Leiden, the Netherlands from January to November 2018. The study protocol was reviewed and approved by the Beoordeling Ethiek Biomedisch Onderzoek Foundation Review Board (Assen, the Netherlands) prior to initiation of the study. The study was conducted according to the Dutch Act on Medical Research Involving Human Subjects and in compliance with good clinical practice. Twelve healthy, nonsmoking male subjects aged 18-65 years and body mass index between 18 and 35 kg/m 2 were included in this study. Subjects with a history or evidence of lung disease were excluded from this study.
| Study design
This was an open-label, 4-way crossover study. Visits were planned with a washout period of 3-7 days. Salbutamol and tobramycin were determined suitable medication to use in this proof-of-concept study, because they are commonly used, are available for intravenous use and inhalation, and have ample data available regarding plasma pharmacokinetics. Subjects were administered 1 mg/kg tobramycin intravenous (Obracin diluted in 50-100 mL 0.9% NaCl) over 30 min, 250 or 500 μg salbutamol by intravenous infusion (Ventolin Injection 0.5 mg/mL) over 2-8 min, 170 mg tobramycin (Vantobra) by inhalation using a Medix AC2000 nebulizer (Clement Clarke International) or 400 μg salbutamol (Ventolin Evohaler, GSK, London, UK) by inhalation with a spacer device (Volumatic).
Paired EBC and plasma samples were collected at 2 (salbutamol) or −15 and 5 (tobramycin) min pre-dose and at 10, 20, 40, 60, 80, 120, 180, 240, 300 and 420 min postdose. Additional plasma and EBC samples were collected from 8 subjects at 600 and 720 min dose after inhaled administration.
| Sample collection and analysis
EBC was collected according to European Respiratory Society guidelines during 5 min of tidal breathing using the Ecoscreen (Jaeger, Hoechberg, Germany). 19 
| Statistics and pharmacokinetic analysis
As this was an exploratory study, no formal power analysis was performed. Pharmacokinetic endpoints were summarized descriptively.
When tobramycin or salbutamol was undetectable, 50% of the lowest estimated concentration was imputed for graphical and statistical purposes. Descriptive analysis was performed using SPSS Version 25 (IBM, Armonk, NY, USA). Pharmacokinetic parameters were calculated using R version 3.5.2. 20 The area under the curve (AUC) was calculated as AUC 0-last for EBC parameters and extrapolated to infinity (AUC inf ) for plasma parameters using the terminal elimination rate constant, determined by the log-linear regression of the last observations above the lower limit of quantification (LLOQ). The bioavailability (F)
What is already known about this subject • Knowledge of drug concentration in lung tissue could aid in the development of pharmacokinetic models of drugs acting in the lung.
• Exhaled breath condensate is a noninvasive sampling matrix for the epithelial lining fluid of the lung.
• Several drugs have already been detected in single exhaled breath condensate samples.
What this study adds
• Measurable salbutamol and tobramycin concentrations are present in serial exhaled breath condensate samples after inhaled administration.
• Variability appears to be high and hampers reliable pharmacokinetic analysis.
• Using exhaled breath condensate urea concentration to correct for dilution in serial samples does not improve variability.
was calculated on an individual level and summarized descriptively.
When insufficient data were available for the log-linear regression, the AUC inf was not included in the results and the mean AUC inf was imputed for the calculation of the bioavailability (F). The clearance and volume of distribution were calculated and corrected for by an individual's F. Promasys software (OmniComm, Fort Lauderdale, FL, USA) was used for data management.
| RESULTS

| Subjects, safety and tolerability
Twelve healthy male volunteers were included, and all subjects completed the 4 study days. Baseline characteristics are shown in Table 1 . Twelve subjects received 1 mg/kg tobramycin by intravenous infusion, 250 μg (3 subjects) or 500 μg (9 subjects) salbutamol by intravenous infusion, 170 mg tobramycin by inhalation and 400 μg salbutamol by inhalation.
| Pharmacokinetics
Mean (± SD) plasma and EBC concentration-time curves of all subjects after intravenous and inhaled administration of tobramycin and salbutamol are shown in Figure 1 . Pharmacokinetic parameters are summarized in Table 2 . Individual concentration-time curves can be found in Supplementary Figure S1 Figure S3 ). 
| Urea and dilution
| DISCUSSION
In this study, the potential of EBC as a matrix for pharmacokinetic analysis of drugs acting in the lungs was investigated. A 4-way crossover study was conducted wherein we obtained serial paired plasma and EBC samples after intravenous and inhaled administration of tobramycin and salbutamol.
The plasma pharmacokinetics after administration of intravenous and inhaled salbutamol and tobramycin were determined. Calculated pharmacokinetic parameters of salbutamol in plasma corresponded with results reported in other studies regarding maximum plasma concentration (C MAX ), time to C MAX and half-life. 21, 22 Plasma C MAX of inhaled tobramycin was lower than expected, which may be a result of the chosen administration technique. 23 We are the first to report serial EBC drug concentrations. We were unable to measure salbutamol and tobramycin in EBC after intravenous administration of salbutamol and tobramycin in 97.5 and 100% of the samples, respectively. Low concentrations were expected in the case of tobramycin, considering the fact that tobramycin is a large (molecular weight 467.52 g/mol), polarized molecule and therefore does not easily pass barriers. This is illustrated by the poor bioavailability of inhaled tobramycin. However, we expected salbutamol to be detectable in more samples, considering that salbutamol is a smaller molecule (molecular weight 239.32 g/mol) and the fact that several researchers have demonstrated the ability to detect intravenously or orally administered drugs with similar properties in exhaled breath or EBC. [13] [14] [15] [16] We assume that salbutamol plasma concentrations were insufficient after administration in order to achieve EBC salbutamol concentrations larger than the LLOQ, even with the high intravenous dose of 500 μg. This hypothesis should be confirmed with a more sensitive assay with a lower LLOQ.
Salbutamol and tobramycin were detected in EBC after inhalation of 400 μg salbutamol and 170 mg of tobramycin. Mean salbutamol concentrations in EBC after inhaled administration decreased below the LLOQ after approximately 2 h, which is about 50% of the amount of time salbutamol is believed to have an effect on pulmonary function. 24 The highest EBC salbutamol concentrations were present during the absorption phase of salbutamol in plasma after inhaled administration. This indicates that higher EBC concentrations are detected when there is active exchange of salbutamol between the After all, EBC reflects a dilution of the ELF. 8, 19 Variation in dilution factors of EBC samples has been a frequently hypothesized cause of variability. Urea has been proposed as marker for dilution in EBC. 12, 25 We measured urea concentrations in EBC and calculated the estimated dilution. Mean D EBC was slightly lower than reported in other studies 10, 25, 26 and varied greatly between and within subjects (Supplementary Figure S4) , providing an explanation for the observed variability. The CV increased after correction, which did not meet our hypothesis regarding reduced variability.
EBC research in general has been plagued by high variability within and between subjects. 9, 19, 27 While several authors have reported methods to reduce variability, [10] [11] [12] 25 this too is poorly reproducible and has not resulted in the development of clear guidelines with standardized methods. 19 Consequently, EBC has not yet reached clinical practice. The fact that 2 commonly used respiratory drugs could not be detected in EBC for the majority of samples postinhalation appears to disqualify EBC as a matrix for pharmacokinetic analysis.
This study has limitations. Variation in inhalation technique could explain the lower than expected plasma concentrations of tobramycin, but also the variability in measured EBC concentrations. 28 In addition, although the EBC device contains a saliva trap, it cannot not be excluded that samples taken directly after administration represent oropharyngeal salbutamol deposition rather than lung pharmacokinetics. Furthermore, almost all sample concentrations were below or on the lower end of the calibration curve. Variability may therefore also result from assay variability as opposed to biological or device variability. 7 Finally, the method to use estimated sample concentrations below the LLOQ, as well as impute 50% of the lowest concentration when no estimation was possible, is a debated subject. 29 Nevertheless, the use of other methods would not change the main outcome 
| CONCLUSION
In conclusion, salbutamol and tobramycin can be quantified in EBC after inhaled administration, especially during the plasma absorption phase, but not after intravenous administration. The high amount of variability of EBC drug concentrations seems to preclude its use for robust pharmacokinetic analysis and as such, we do not recommend its use in this area.
